Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lapatinib ditosylate

(luh-PA-tih-nib dy-TOH-sih-layt)
A drug used with capecitabine or letrozole to treat certain types of HER2-positive breast cancer that are advanced or have spread. It is also being studied in the treatment of other types of cancer. Lapatinib ditosylate blocks EGFR and other proteins, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Lapatinib is the active ingredient of lapatinib ditosylate. Also called GW572016 and Tykerb.
More Information
Search NCI's Dictionary of Cancer Terms